Sanofi-Aventis To File For Menactra Use In Infants
This article was originally published in The Pink Sheet Daily
Firm sees pharmacoeconomic advantage for two-dose regimen at nine and 12 months.
You may also be interested in...
Early C. difficile program comes along with $550 million deal.
Next step for Pentacel is the June 25 ACIP Vaccines for Children vote.
Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.